Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC).

Sartor says more cellular studies need to be done with sipleucel-T in order to better understand the immune response and changes in the cells of patients treated with this agent.

Additionally, Sartor says, the activity of immunotherapy in ethnic groups should be explored further.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immuno-Oncology

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC